SCHEDULE 13D/A: RA Capital Increases Stake in Mineralys Therapeutics to 9.9% Following $17.5 Million Public Offering Investment

RA Capital Management and its affiliates have significantly increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.9% of outstanding common stock through a recent $17.5 million investment in a public offering.

Summary

• This document is Amendment No. 2 to a Schedule 13D filing, updating beneficial ownership information for Mineralys Therapeutics, Inc.
• The filing is made by RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons").
• On March 13, 2025, RA Capital Healthcare Fund, L.P. purchased 1,296,296 shares of common stock at $13.50 per share from underwriters in Mineralys Therapeutics' 2025 public offering.
• The aggregate purchase price for these shares was $17,499,996, funded by the Fund's working capital.
• As a result of this transaction, RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah collectively beneficially own 6,287,597 shares of Mineralys Therapeutics common stock, representing 9.9% of the class.
• RA Capital Healthcare Fund, L.P. beneficially owns 4,358,979 shares, representing 6.9% of the class.
• The beneficial ownership includes 4,280,051 shares held directly by the Fund, 1,867,229 shares held by RA Capital Nexus Fund III, L.P., and 61,389 shares underlying vested and soon-to-vest stock options held by Dr. Derek DiRocco for the benefit of RA Capital.
• The Fund also holds Pre-Funded Warrants to acquire 549,755 shares, subject to a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 49,835,637 shares outstanding as of February 7, 2025, plus 12,962,962 shares issued in the 2025 Offering, and exercisable options/warrants.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A major investment firm significantly increasing its stake in the company, especially through a public offering, generally signals confidence. While it's an ownership disclosure, the nature of the transaction is a positive indicator for the company's prospects.

Positives

• A significant investment of $17.5 million by a prominent healthcare-focused investment firm (RA Capital) indicates confidence in Mineralys Therapeutics, Inc.'s prospects.
• The increased beneficial ownership to 9.9% by RA Capital Management and its affiliates signals a strong, long-term commitment to the company.

Risks

• The Pre-Funded Warrants held by RA Capital Healthcare Fund, L.P. contain a "Beneficial Ownership Blocker" which prevents the Fund from exercising warrants if it would result in beneficial ownership exceeding 9.99% of the common stock outstanding, limiting the Fund's ability to further increase its stake through these warrants.

Future Outlook

The document indicates future vesting of stock options for Dr. Derek DiRocco, with various tranches vesting monthly through at least May 2025. Additionally, a 60-day lock-up period for executive officers and directors, including Dr. DiRocco, is in effect from March 11, 2025, restricting sales or transfers of common stock.

Industry Context

This filing reflects a significant institutional investment in a biotechnology company, a common occurrence in the life sciences sector where specialized funds like RA Capital Management actively participate in funding and supporting emerging therapeutic companies. The increased stake by a prominent healthcare investor could be viewed positively by the market, signaling confidence in Mineralys Therapeutics' drug development pipeline or strategic direction.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased institutional ownership by RA Capital Management may enhance investor confidence and potentially stabilize or positively influence the stock price.
• Employees: The continued vesting of stock options for Dr. DiRocco, a key individual associated with RA Capital, indicates ongoing alignment of interests and potential long-term commitment.

Next Steps

• Continued vesting of stock options for Dr. Derek DiRocco, with various installments scheduled through at least May 13, 2025.
• The 60-day lock-up period for executive officers and directors will expire around May 10, 2025, allowing for potential sales or transfers of common stock thereafter, subject to specified exceptions.

Key Dates

Keywords

Mineralys Therapeutics, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Public Offering, Stock Investment, Healthcare Fund, Biotechnology, Pharmaceuticals, Institutional Investor